LAUSR

Chronic myelomonocytic leukemia (CMML) is a clonal, hematopoietic stem cell disorder, characterized by sustained peripheral blood (PB) monocytosis and an inherent risk for blast phase (BP) disease.1, 2 Blast phase, as defined by ≥20% PB or bone marrow (BM) blasts,1 has a reported incidence ranging from 15% to 29%.1, 2 Risk factors for CMML-BP have included high risk karyotype,3, 4 PB blast %,5, 6 circulating immature myeloid cells (IMC),6 absolute monocyte count (AMC) >10 × 10(9)/L,5, 6 ASXL1, RUNX1, NRAS, SETBP1, DNMT3A and NPM1 mutations.7, 8 In CMML, while predictors for BP have been identified, not much is known about prognostication, optimal treatment modalities and survival outcomes. We carried out this large, collaborative, two institution study (Mayo Clinic, Minnesota and the MD Anderson Cancer Center, Texas) with the intent to examine i) prognostic factors, ii) survival trends, and iii) treatment outcomes in patients with CMMLBP.